Quantifying Hepatitis B Virus DNA in Chronic Carriers
Author Information
Author(s): Mendy Maimuna E, Kaye Steve, van der Sande Marianne, Rayco-Solon Pura, Waight Pauline A, Shipton Deborah, Awi Dorka, Snell Paul, Whittle Hilton, McConkey Samuel J
Primary Institution: Medical Research Council, The Gambia
Hypothesis
The study aimed at developing a real-time quantitative PCR assay to monitor HBV serum virus load of chronic carriers enrolled in therapeutic trials.
Conclusion
The method is reliable, accurate, and reproducible for monitoring HBV therapy efficacy.
Supporting Evidence
- The qPCR assay showed good intra- and inter-assay reproducibility.
- Viral load levels dropped dramatically during lamivudine therapy.
- HBV DNA was detected in 77.0% of HBeAg negative carriers.
- The method had a lower threshold of detection than the commercial assay.
- Correlation between the new assay and a commercial assay was high (r = 0.91).
- Viral load was lower with increasing age in both HBeAg positive and negative carriers.
Takeaway
Researchers created a new test to measure the amount of hepatitis B virus in people's blood, which helps doctors see how well treatments are working.
Methodology
Quantitative real-time PCR assay was performed using SYBR-Green signal detection and specific primers.
Limitations
The study primarily involved asymptomatic carriers and may not represent all HBV-infected individuals.
Participant Demographics
Two groups: 22 male carriers aged 15-25 and 318 chronic carriers aged 1-73.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website